DP
Therapeutic Areas
Biodexa Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| eRapa | Familial Adenomatous Polyposis (FAP) | Phase 3 |
| MTX240 (OPB-171775) | TKI-Resistant Gastrointestinal Stromal Tumors (GIST) | Phase 1/2 |
| Tolimidone | Type 2 Diabetes | Phase 2 |
Leadership Team at Biodexa Pharmaceuticals
SS
Stephen Stamp
Chief Executive Officer / Chief Financial Officer
GS
Gary Shangold
Chief Medical Officer